Sandra L Hatten Net Worth

The estimated Net Worth of Sandra L Hatten is at least 87.5 千$ dollars as of 12 December 2019. Sandra Hatten owns over 3,072 units of Mallinckrodt Plc stock worth over 18,960$ and over the last 11 years Sandra sold MNK stock worth over 68,492$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sandra Hatten MNK stock SEC Form 4 insiders trading

Sandra has made over 6 trades of the Mallinckrodt Plc stock since 2014, according to the Form 4 filled with the SEC. Most recently Sandra sold 3,072 units of MNK stock worth 22,211$ on 12 December 2019.

The largest trade Sandra's ever made was selling 6,290 units of Mallinckrodt Plc stock on 10 August 2018 worth over 30,884$. On average, Sandra trades about 1,416 units every 122 days since 2014. As of 12 December 2019 Sandra still owns at least 55,765 units of Mallinckrodt Plc stock.

You can see the complete history of Sandra Hatten stock trades at the bottom of the page.

What's Sandra Hatten's mailing address?

Sandra's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, BLOCK 10-1 BLANCHARDSTOWN CORP. PARK, DUBLIN, L2, 15.

Insiders trading at Mallinckrodt Plc

Over the last 11 years, insiders at Mallinckrodt Plc have traded over 29,853,069$ worth of Mallinckrodt Plc stock and bought 2,559,592 units worth 174,429,961$ . The most active insiders traders include & Co. Inc. Paulson、James E Deerfield Mgmt L.P....、Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of 10,061$. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth 9,495$.

What does Mallinckrodt Plc do?

mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit

Complete history of Sandra Hatten stock trades at Avadel Pharmaceuticals plc、Mallinckrodt Plc

Mallinckrodt Plc executives and stock owners

Mallinckrodt Plc executives and other stock owners filed with the SEC include:

• Mark Trudeau,
  President, Chief Executive Officer, Director
• Steven Romano,
  Executive Vice President, Chief Scientific Officer
• Hugh O'Neill,
  Executive Vice President, Chief Commercial Officer
• Mark Casey,
  Executive Vice President and Chief Legal Officer
• Bryan Reasons,
  Chief Financial Officer, Executive Vice President
• Ian Watkins,
  Chief Human Resource Officer, Executive Vice President
• Angus Russell,
  Independent Non-Executive Chairman of the Board
• JoAnn Reed,
  Independent Director
• J. Martin Carroll,
  Independent Director
• David Norton,
  Independent Director
• Kneeland Youngblood,
  Independent Director
• Anne Whitaker,
  Independent Director
• Paul Carter,
  Independent Director
• Carlos Paya,
  Independent Director
• Daniel Speciale,
  Vice President - Investor Relations and IRO
• David R Carlucci,
  Director
• Virgil D Thompson,
  Director
• Diane H. Gulyas,
  Director
• Matthew K Harbaugh,
  SVP&Chief Financial Officer
• Michael Bryant Hicks,
  Sr. VP & General Counsel
• Ronald K. Lloyd,
  Sr. VP & Pres, Hospital
• Raymond J. Furey,
  SVP & Chief Compliance Officer
• Gary M. Phillips,
  Sr. VP & Chief Strategy Ofcr.
• Meredith B Fischer,
  SVP, Communic. & Public Affair
• Melvin D Booth,
  Director
• Joseph A Zaccagnino,
  Director
• Coleman N Iii Lannum,
  VP, Investor Relations
• Dagmar Rosa Bjorkeson,
  Chief Strat & Corp Dev Officer
• Sigurdur O Olafsson,
  President and CEO
• Kassie Harrold,
  Chief Compliance Officer
• Jason Daniel Goodson,
  EVP & Head of Corp Development
• Henriette Nielsen,
  EVP & Chief Transformation OFC
• Lisa French,
  EVP & Chief Commercial Officer
• Mark Anthony Tyndall,
  EVP & Chief Legal Offi & Secre
• Stephen Andrew Welch,
  EVP & Head of Spec Generics
• Frank Scholz,
  SVP, Global Operations
• George A. Kegler,
  EVP & CFO, Interim
• Karen Patruno Sheehy,
  Sr. VP & Chief Compliance Off.
• James E Deerfield Mgmt L.P....,
  
• Don M Bailey,
  Director
• Sandra L Hatten,
  Sr. Vice President Quality
• Terrance L Carlson,
  Interim General Counsel
• & Co. Inc. Paulson,
  10% owner
• Holding Ltd Enceladus,
  
• Thomas E Berry,
  See Remarks
• Peter G Edwards,
  See Remarks
• Stefano R Carchedi,
  See Remarks
• Stephen Merrick,
  See Remarks
• Nancy Lurker,
  Director
• Mario D. Saltarelli,
  Sr. VP & Chief Science Ofcr.
• Kathy A Schaefer,
  Sr. VP Fin & Corp. Controller
• Peter C Richardson,
  EVP & Chief Scientific Officer
• Daniel Arthur Celentano,
  Director
• Woodrow A Jr Myers,
  Director
• Paul Bisaro,
  Director
• James R Sulat,
  Director
• Susan Michele Silbermann,
  Director
• Karen Ling,
  Director
• Neal P Goldman,
  Director
• Riad Hussein El Dada,
  Director